

Significant events in **respiratory syncytial virus (RSV)** vaccination practice in Australia

Year	Month	Intervention
2023	November	First recombinant neutralising human immunoglobulin G1 kappa (IgG1κ) long-acting monoclonal antibody, nirsevimab (Beyfortus), registered for use in neonates and children up to 24 months of age for RSV protection through passive immunisation
2024	January	First RSV vaccine – adjuvanted recombinant RSV pre-fusion F protein vaccine (Arexvy) – registered for use in individuals aged ≥60 years
	February	Arexvy made available through private prescription
	March	<p>Second RSV vaccine – bivalent recombinant RSV pre-fusion F protein vaccine (Abrysvo) – registered for use in pregnant women between 24 and 36 weeks gestation and individuals aged ≥60 years</p> <p>NSW Health RSV Vulnerable Babies Program provides free nirsevimab for medically at-risk infants and young children from March to September</p> <p>ATAGI recommends:</p> <ul style="list-style-type: none"> • a single dose of RSV vaccine for: <ul style="list-style-type: none"> ○ adults aged ≥75 years ○ Aboriginal and Torres Strait Islander people aged ≥60 years ○ adults aged ≥60 years who have a medical condition that increases the risk of severe RSV disease ○ pregnant women at 28–36 weeks' gestation • a single dose of nirsevimab for neonates and infants aged <8 months whose mothers were not vaccinated at least two weeks before delivery or who are at increased risk of severe RSV disease
	April	<p>Queensland Paediatric Respiratory Syncytial Virus Prevention (QPRSVP) Program provides free nirsevimab for all newborn infants and medically at-risk young children</p> <p>Western Australia RSV infant immunisation program provides free nirsevimab for all newborn infants and medically at-risk young children from April to September</p> <p>Nirsevimab not available outside of state-funded programs in 2024</p>
	June	<p>RSV chapter of the <i>Australian Immunisation Handbook</i> published to provide clinical information and recommendations for use of RSV immunisation products</p> <p>Abrysvo available on private prescription</p>
2025	February	<p>Maternal RSV immunisation program provides free Abrysvo under the NIP for pregnant women at 28–36 weeks gestation (prior to 37 weeks) to protect their baby</p> <p>Additionally, states and territories provide nirsevimab for free under neonate or catch-up programs in 2025 to eligible infants and children including:</p> <ul style="list-style-type: none"> • infants up to 8 months: <ul style="list-style-type: none"> ○ whose mother did not receive the RSV vaccine during pregnancy ○ who were born within 2 weeks after the mother receiving an RSV vaccine ○ who have a condition or circumstance that increases their risk of severe RSV disease • young children aged 8 months to under 2 years who have certain risk conditions for severe RSV disease are recommended to receive the RSV immunisation product before their second RSV season

Year	Month	Intervention
2025 cont.	March	First mRNA RSV F protein vaccine (mRESVIA) registered for use in adults ≥ 60 years of age Age for which Arexvy indicated for use extended to include individuals 50–59 years who are at increased risk for RSV disease
	July	Victoria's older adult RSV program provides free Arexvy to residents aged ≥ 60 years in public and Aboriginal and Torres Strait Islander community-controlled aged care services
2026	February	Abrysvo recommended in each pregnancy from 28 weeks' gestation
	April	Arexvy funded under NIP for all adults aged ≥ 75 years and Aboriginal and Torres Strait Islander people aged ≥ 60 years